At the time of writing, Cytokinetics Inc [CYTK] stock is trading at $60.04, down -0.45%. An important factor to consider is whether the stock is rising or falling in short-term value. The CYTK shares have gain 5.39% over the last week, with a monthly amount glided 12.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on April 24, 2025, and set its price target to $55. On February 07, 2025, Citigroup initiated with a Buy rating and assigned a price target of $86 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $80 on January 22, 2025. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $80 as its price target on November 08, 2024. Goldman downgraded its rating to Neutral for this stock on August 13, 2024, and downed its price target to $60. In a note dated January 24, 2024, UBS downgraded a Neutral rating on this stock and boosted its target price from $61 to $92.
For the past year, the stock price of Cytokinetics Inc fluctuated between $29.31 and $61.48. Currently, Wall Street analysts expect the stock to reach $86 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $60.04 at the most recent close of the market. An investor can expect a potential return of 43.24% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
According to Cytokinetics Inc [NASDAQ:CYTK], the company’s sales were 85.74M for trailing twelve months, which represents an 26714.86% jump. Gross Profit Margin for this corporation currently stands at -2.27% with Operating Profit Margin at -6.38%, Pretax Profit Margin comes in at -7.07%, and Net Profit Margin reading is -7.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 3.09 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Cytokinetics Inc [NASDAQ:CYTK] has a current ratio of 6.76. On the other hand, the Quick Ratio is 6.76, and the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 83.79.
Transactions by insiders
Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on Oct 07 ’25 when 2000.0 shares were sold. Director, Kaye Edward M. MD completed a deal on Oct 06 ’25 to sell 6757.0 shares. Meanwhile, Director EDWARD KAYE bought 6757.0 shares on Oct 06 ’25.
